EUVIMEDOntdek EUVIMED
CrossrefInfokaart

Trial‐based economic evaluation of mindfulness‐based cognitive therapy compared to treatment as usual for bipolar disorder

Ben Wijnen, Maud Jansen, Annelieke van Velthoven, Imke Hanssen, Marloes Huijbers, Silvia Evers, Anne Speckens

International Journal of Methods in Psychiatric Research · 2024-03 · 33 (1)

DOI: 10.1002/mpr.1981 ↗
SamenvattingBibliografische gegevens

Samenvatting

Abstract Objective Aim of this study was to assess the cost‐effectiveness and cost‐utility of mindfulness‐based cognitive therapy (MBCT) and treatment as usual (TAU) compared to TAU alone in adults with Bipolar disorder (BD). Methods An economic evaluation with a time horizon of 15 months was conducted from a societal perspective. Outcomes were expressed in costs per quality adjusted life years (QALYs) and costs per responder using the inventory of depressive symptomatology clinician rating score. Results People with BD ( N = 144) were included in this study. From a societal perspective, the difference of total costs between MBCT + TAU and TAU was €615, with lower costs in the MBCT + TAU group. Only healthcare costs differed significantly between the two groups. A small difference in QALYs in favor of MBCT + TAU was found combined with lower costs (−€836; baseline adjusted) for MBCT + TAU compared to TAU, resulting in a dominant incremental cost‐utility ratio. The probability that the MBCT + TAU was cost‐effective was 65%. All sensitivity analyses attested to the robustness of the base case analyses. Conclusion Concludingly, MBCT + TAU seems to be cost‐effective compared to TAU alone, indicated by a small or neglectable difference in effect, in favor of MBCT + TAU, while resulting in lower costs.

Kennis die bij uw werk past.

Van een gratis start via persoonlijk literatuuronderzoek tot de volledige Research Suite.

Tarieven bekijken →

Zijn alle volledige uitgeversteksten inbegrepen?

Nee. Bibliografische records, abstracts en volledige teksten zijn verschillende inhoudstypen. Beschikbaarheid hangt af van bron, open access en bestaande licenties. Een EUVIMED-abonnement vervangt geen aanvullende uitgeversrechten.

Tarieven bekijken →